Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2Other hematologic neoplasm 2Head & Neck 2Genitourinary 2Gastrointestinal 2Thoracic 1Sarcoma 1Plasma cell 1Other 1Lymphoid 1

Conditions

Prostatic Neoplasms 1Kidney Diseases 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sodium Bicarbonate × Genitourinary × Clear all
NCT06661902 2026-02-17

BURN

University of Washington

Phase 1/2 Completed
350 enrolled
Genitourinary

Prostatic Neoplasms

NCT00540904 2014-03-03

Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate

Barretos Cancer Hospital

Phase 2 Completed
27 enrolled
Genitourinary

Kidney Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡